Abbott Laboratories vs. DiaMedica Therapeutics Inc. Common Stock
ABT
Abbott Laboratories
$110.91 +1.08%
VS DMACDiaMedica Therapeutics Inc. Common Stock
$6.84 -0.44%
Abbott Laboratories and DiaMedica Therapeutics Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| ABT | DMAC | |
|---|---|---|
| Market Cap | $189.86 billion | $370.47 million |
| Net Income (TTM) | — | $-37,541,000 |
ABT leads on 1 of 1 size & scale factors.
Valuation
| ABT | DMAC | |
|---|---|---|
| Price / Book | — | 9.66 |
ABT and DMAC split the valuation factors evenly.
Profitability
| ABT | DMAC | |
|---|---|---|
| Return on Equity | — | -97.92% |
ABT and DMAC split the profitability factors evenly.
Dividend
| ABT | DMAC | |
|---|---|---|
| Dividend Yield | 2.27% | — |
ABT and DMAC split the dividend factors evenly.
Risk & Sentiment
| ABT | DMAC | |
|---|---|---|
| Short Interest | 0.57% | 0.05% |
DMAC leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, DMAC overview, DMAC financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.